cms.bioaccessla.com

Tag: Latin America

  • Master Early Feasibility Studies for Medical Devices Under COFEPRIS

    Master Early Feasibility Studies for Medical Devices Under COFEPRIS

    Introduction

    Understanding the regulatory landscape for medical devices is crucial for innovators aiming to bring their products to market, particularly in Mexico, where COFEPRIS oversees clinical trials and safety standards. This article serves as a comprehensive guide to mastering early feasibility studies under COFEPRIS, enabling researchers and developers to streamline their submissions and enhance compliance. As the regulatory framework evolves, it is essential to identify the key challenges and strategies that can ensure a successful approval process.

    Understand COFEPRIS: Mexico’s Regulatory Authority for Clinical Trials

    The Federal Commission for the Protection against Sanitary Risk serves as Mexico’s principal regulatory authority, overseeing and ensuring the safety and effectiveness of medical devices. A thorough understanding of this regulatory agency is essential for navigating the complex regulatory landscape, particularly regarding . Consider the following key aspects:

    1. Mission and Vision: The organization is committed to , which underpins its regulatory decisions and actions.
    2. Key Regulations: It is vital to familiarize yourself with the governing in Mexico, as these establish the compliance framework. Importantly, the new , are anticipated to streamline the approval process for high-risk products, potentially reducing approval times by up to 30%.
    3. Organizational Structure: Grasping the agency’s departmental structure and their specific functions can facilitate your inquiries and submissions, ensuring they are directed to the appropriate channels.
    4. : The health authority frequently updates its guidelines. Staying informed through newsletters or the official health agency website is crucial for keeping abreast of these changes.

    By understanding these aspects, you can effectively navigate the complexities of the Mexican regulatory landscape, facilitating more efficient submissions and endorsements for . Partnering with bioaccess® can significantly enhance your understanding and navigation of the approval process. With over 20 years of experience in managing , bioaccess® offers , ensuring effective and comprehensive , including feasibility assessments, site selection, compliance reviews, trial setup, import permits, project management, and reporting.

    The center shows COFEPRIS, and the branches represent important areas to focus on. Each branch gives you insights into what you need to know about the regulatory authority.

    Review COFEPRIS Requirements for Early Feasibility Studies

    Before embarking on for medical devices under COFEPRIS, it is imperative to conduct a thorough review of the specific requirements to ensure . Key requirements include:

    1. : A comprehensive must be developed, outlining the project’s objectives, methodology, and statistical analysis plans. This document serves as the foundation for your research and is critical for . Essential components of a for COFEPRIS encompass a , a robust statistical plan, and a detailed timeline for execution.
    2. : Clear and concise informed consent documents are essential to adhere to ethical standards. Statistics reveal that compliance with is vital for maintaining participant trust and ensuring ethical integrity in . Research indicates that 95% of participants feel more secure when informed consent procedures are transparent and effectively communicated.
    3. : This document should encompass detailed information about the medical device, including preclinical data and safety information. A well-organized brochure enhances the credibility of the study and aids in the evaluation process.
    4. : Securing approval from a recognized ethics committee is mandatory prior to submission to COFEPRIS. Engaging with local ethics committees at the outset can streamline this process and foster collaboration. Regulatory expert Katherine Ruiz emphasizes, “Early interaction with ethics committees can significantly shorten review times and improve the quality of submissions.”
    5. Regulatory Submission Documents: Compile all necessary documents, including the application form, , and , for submission to the health regulatory authority. Ensuring that these documents are comprehensive and accurate is crucial for expediting the authorization process.

    By adhering to these requirements and integrating the latest protocols for for medical devices under COFEPRIS, researchers can enhance the likelihood of a successful submission and facilitate a more streamlined process for conducting early assessments in Mexico. Furthermore, leveraging the expertise of bioaccess® can substantially accelerate the timeline, enabling quicker patient enrollment and more effective in the Latin American Medtech sector, potentially reducing approval durations to 6-8 weeks.

    Each box represents a step you need to follow for the COFEPRIS requirements. Follow the arrows to see the order of steps, starting from the Research Protocol all the way to successfully submitting your study.

    Follow the Submission Process for Early Feasibility Studies

    To effectively navigate the submission process for under COFEPRIS, it is imperative to follow these essential steps:

    1. : Ensure that all necessary documents are meticulously organized and formatted in accordance with the relevant guidelines. This includes a comprehensive research protocol, informed consent forms, and any necessary supporting documentation.
    2. Submit Electronically: Utilize the online platform for your application submission. Confirm that all digital signatures are in place and that all documents are correctly uploaded to avoid delays.
    3. : Be mindful of the fees associated with your submission. For research protocol approval, the . Prompt payment is essential to avoid any disruptions in the review procedure.
    4. Track Your Submission: After submitting your application, actively . This enables you to quickly respond to any inquiries or requests for further information, which can greatly accelerate the authorization timeline.
    5. : Be prepared to engage with COFEPRIS regarding any feedback or requests for clarification. An anticipatory method in tackling issues can enable a more streamlined endorsement process, guaranteeing that your research advances without unwarranted holdups.

    By adhering to these best practices, you can significantly enhance the likelihood of a successful submission and acceptance for for medical devices under COFEPRIS, ultimately expediting your path to market. Furthermore, leveraging bioaccess® services, such as compliance evaluations and project oversight, can facilitate enrollment in 50% faster than conventional markets, owing to their expertise in managing early-feasibility, , pilot, pivotal, and post-market follow-up research.

    Each box represents a crucial step in submitting your research for approval. Follow the arrows to understand the flow from preparing your documents to responding to feedback.

    Navigating the can present significant challenges that may impede . To effectively address these hurdles, consider implementing the following strategies:

    1. Anticipate : Understanding frequent causes of delays, such as incomplete documentation or ambiguous study protocols, is crucial. The regulatory authority often encounters submissions that lack clarity, which can prolong the review duration.
    2. Maintain : Establishing a direct line of communication with regulatory representatives can clarify uncertainties and provide essential guidance throughout the approval process.
    3. Engage Local Experts: Collaborating with who possess in-depth knowledge of COFEPRIS procedures can offer valuable insights and streamline your application. At bioaccess®, our team brings over 20 years of expertise in overseeing , including Early-Feasibility, , and Pivotal Research, ensuring that your trials are compliant and efficient.
    4. Be : Ensure your research site is audit-ready by maintaining . The regulatory body may conduct audits to ensure compliance, and being prepared can expedite the timeline for authorization.
    5. Stay Flexible: Adaptability is key; be ready to modify your research design or protocols based on feedback from the regulatory authority. This responsiveness can significantly enhance your chances of receiving prompt consent.

    By proactively addressing these common challenges and utilizing strategic methods, you can navigate the intricacies of the regulatory endorsement more efficiently, ultimately facilitating your . With bioaccess®’s , you can effectively navigate the COFEPRIS approval process by leveraging their expertise in and compliance reviews.

    Each box represents a strategy to overcome challenges in the COFEPRIS approval process. Follow the arrows to see the recommended steps to take for a more efficient approval journey.

    Conclusion

    Understanding the intricacies of COFEPRIS is paramount for successfully conducting early feasibility studies for medical devices in Mexico. This regulatory authority plays a crucial role in ensuring the safety and effectiveness of medical innovations, making it essential for stakeholders to navigate its requirements effectively. By grasping the fundamental aspects of COFEPRIS, including its mission, regulations, and submission processes, researchers and developers can streamline their path to regulatory approval.

    Key insights from the article highlight the importance of:

    • A well-prepared submission package
    • Adherence to ethical standards
    • Proactive communication with regulatory representatives

    Compliance with COFEPRIS requirements, such as thorough research protocols and informed consent forms, is critical for minimizing delays and enhancing the likelihood of approval. Engaging local experts and maintaining flexibility in research design further contribute to overcoming common challenges associated with the approval process.

    In conclusion, the significance of early feasibility studies in medical device development cannot be overstated. By equipping oneself with the knowledge and resources necessary to navigate COFEPRIS regulations, stakeholders can accelerate their research timelines and ultimately bring innovative medical solutions to market more efficiently. Embracing the expertise offered by organizations like bioaccess® can provide invaluable support in this endeavor, ensuring that clinical trials are conducted with precision and compliance, paving the way for advancements in healthcare.

    Frequently Asked Questions

    What is COFEPRIS and what is its role in Mexico?

    COFEPRIS, the Federal Commission for the Protection against Sanitary Risk, is Mexico’s principal regulatory authority responsible for overseeing clinical trials and ensuring the safety and effectiveness of medical devices.

    What is the mission and vision of COFEPRIS?

    COFEPRIS is committed to safeguarding public health and safety, which serves as the foundation for its regulatory decisions and actions.

    What key regulations should one be familiar with when dealing with COFEPRIS?

    It is important to be familiar with the General Health Law and other relevant regulations governing clinical trials in Mexico, as these establish the compliance framework for submissions.

    What are the new Good Manufacturing Practices (GMP) and when do they take effect?

    The new Good Manufacturing Practices (GMP) are set to take effect on November 30, 2025, and are expected to streamline the approval process for high-risk products, potentially reducing approval times by up to 30%.

    How is COFEPRIS organized, and why is this important?

    Understanding COFEPRIS’s departmental structure and specific functions is important for directing inquiries and submissions to the appropriate channels, facilitating more efficient communication.

    How can one stay updated on regulatory changes from COFEPRIS?

    Staying informed about regulatory updates can be achieved by following newsletters or visiting the official health agency website to keep abreast of changes in guidelines.

    How can partnering with bioaccess® assist in navigating COFEPRIS?

    Partnering with bioaccess®, which has over 20 years of experience in managing clinical trials, can enhance understanding and navigation of the approval process, offering tailored solutions for Medtech startups, including feasibility assessments, site selection, compliance reviews, trial setup, import permits, project management, and reporting.

    List of Sources

    1. Understand COFEPRIS: Mexico’s Regulatory Authority for Clinical Trials
      • 10 Trends and Statistics for Clinical Trials in 2023 (https://xtalks.com/10-trends-and-statistics-for-clinical-trials-in-2023-3377)
      • statista.com (https://statista.com/statistics/1203554/mexico-clinical-trials-phase)
      • Master Regulatory Pathways for Medtech in Mexico: A Comprehensive Guide | bioaccess® (https://bioaccessla.com/blog/master-regulatory-pathways-for-medtech-in-mexico-a-comprehensive-guide)
      • expertmarketresearch.com (https://expertmarketresearch.com/reports/mexico-clinical-trials-market)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/mexico)
    2. Review COFEPRIS Requirements for Early Feasibility Studies
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
      • bioaccessla.com (https://bioaccessla.com/es/blog/top-7-challenges-in-mexican-clinical-trial-design-you-need-to-know)
      • A Decade of Innovation in Medical Device Testing – Medical Device Innovation Consortium (https://mdic.org/celebrating-early-feasibility-studies-10-year-journey)
      • Best Practices for Post-Market Study Strategies in Mexico: Ensuring Compliance and Success | bioaccess® (https://bioaccessla.com/blog/best-practices-for-post-market-study-strategies-in-mexico-ensuring-compliance-and-success)
      • meddeviceonline.com (https://meddeviceonline.com/doc/latam-s-regulatory-framework-for-medtech-early-feasibility-studies-0001)
    3. Follow the Submission Process for Early Feasibility Studies
      • clinregs.niaid.nih.gov (https://clinregs.niaid.nih.gov/country/mexico)
      • veraqueconsulting.com (https://veraqueconsulting.com/mx/medical-device-regulatory-overview-in-mexico-veraque)
      • artixio.com (https://artixio.com/post/pharmaceutical-drugs-registration-process-mexico-cofepris)
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
    4. Navigate Challenges in COFEPRIS Approval
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC6167464)
      • bioaccessla.com (https://bioaccessla.com/es/blog/top-7-challenges-in-mexican-clinical-trial-design-you-need-to-know)
      • privacyshield.gov (https://privacyshield.gov/ps/article?id=Mexico-Healthcare-Products-Services)
      • mexicobusiness.news (https://mexicobusiness.news/health/news/cofepris-new-administration-main-challenges-2025)

  • Master MDSAP FDA Compliance: Best Practices for Clinical Research

    Master MDSAP FDA Compliance: Best Practices for Clinical Research

    Introduction

    Navigating the complexities of MDSAP FDA compliance is crucial for medical device manufacturers who want to excel in a competitive landscape. This article explores best practices that clarify compliance requirements, enhance audit preparedness, and boost operational efficiency. With diverse regulations across multiple countries and the potential pitfalls during the audit process, how can organizations ensure they meet these stringent standards while leveraging the strategic advantages that MDSAP provides?

    Understanding these challenges is essential for manufacturers aiming to thrive. By implementing effective strategies, companies can not only comply with regulations but also position themselves for success in the Medtech landscape. The insights shared here will empower organizations to tackle compliance head-on, fostering a culture of continuous improvement and operational excellence.

    Understand MDSAP Compliance Requirements

    To effectively navigate the , manufacturers must first understand its compliance requirements. This program merges with the regulatory mandates of participating nations, including the USA, Canada, Brazil, Japan, and Australia. Key requirements include:

    • : Establish a robust QMS that aligns with ISO 13485 standards, ensuring all processes are documented and controlled. Organizations that implement these regulations effectively can collect and analyze trends to identify nonconformities.
    • : Implement a process that complies with , focusing on identifying, evaluating, and mitigating risks associated with medical devices. The integration of QMS and Systems (RMS) is essential for enhancing device designs and ensuring reliable supply chains.
    • : Stay updated on the specific regulatory requirements of each participating country, as these can vary significantly. For instance, participation in the is mandatory in Canada for class II, III, and IV medical devices since January 1, 2019, while it remains optional in other countries.
    • Documentation: Maintain that demonstrates adherence to both ISO standards and local regulations, including design history files, technical files, and . Effective documentation practices are vital, as auditors assess planning activities regarding purchased products and outsourced processes.

    By understanding these requirements, producers can better prepare for audits and ensure adherence across various markets, ultimately enhancing their operational efficiency and market readiness. Furthermore, it is crucial to identify potential pitfalls in compliance with the MDSAP FDA, such as excessive reliance on risk tools without adequate understanding, which can lead to poor risk-based decisions. Integrating insights from specialists, like Trautman, who emphasizes the necessity for enhanced personnel competency standards, can further assist producers in managing these complexities.

    The central node represents the main topic of MDSAP compliance, while the branches show the key requirements. Each sub-branch provides more detail on what needs to be done under each requirement, helping you understand the full scope of compliance.

    Implement Effective MDSAP Audit Preparation Strategies

    To prepare effectively for an MDSAP audit, manufacturers must adopt strategic approaches that ensure compliance and readiness:

    • Conduct a : Begin by comparing your current (QMS) against MDSAP requirements. This critical evaluation identifies areas needing improvement, covering documentation, processes, and compliance with . As Corrine Bonfiglio from The FDA Group emphasizes, a comprehensive gap evaluation is essential for meeting the latest regulatory expectations set by the MDSAP FDA and ensuring robust preparation.
    • : It’s vital to provide targeted training for personnel involved in the evaluation process. Team members must understand the requirements and their roles in maintaining compliance. Proficiency in is particularly crucial, as it directly influences inspection success rates and aligns with the updated Evaluation Method set to release on February 2, 2026.
    • : Conduct internal mock evaluations to simulate the assessment environment. This proactive practice helps identify potential issues, allowing teams to address them before the actual audit.
    • : Regularly review and update all documentation to ensure it is complete, accurate, and easily accessible. This includes Standard Operating Procedures (SOPs), work instructions, and records of prior evaluations.
    • : Establish early communication with recognized auditing organizations. Their insights into the evaluation process and expectations can significantly enhance your preparation efforts.

    By implementing these strategies, particularly a thorough gap evaluation as illustrated in the case study ‘Gap Assessment for Preparation,’ manufacturers can significantly enhance their readiness for evaluations and improve their chances of achieving compliance.

    Follow the arrows to see the steps you need to take for effective MDSAP audit preparation. Each box represents a key strategy that contributes to your overall readiness.

    Leverage MDSAP for Strategic Market Access and Efficiency

    MDSAP offers several strategic advantages for looking to enhance and operational efficiency:

    • : By participating in MDSAP, manufacturers can undergo a single audit that satisfies the of multiple countries. This approach significantly , saving both time and resources.
    • : The program promotes the integration of quality management systems across various jurisdictions, leading to more efficient processes and minimizing duplication of efforts.
    • : Completing a medical device single assessment boosts a producer’s credibility with regulatory bodies, paving the way for smoother interactions and approvals in future endeavors. As noted by the USFDA, “The FDA will examine reports from the medical device single audit program with a degree of scrutiny proportional to the importance of findings, considering the review and follow-up conducted by the AO.”
    • : This certification enables producers to enter new markets more easily, as the evaluation signifies compliance with international standards, facilitating acceptance from local regulators. The global medical device market is projected to surpass US$673 billion by 2029, highlighting the importance of MDSAP FDA in accessing this growing market.
    • : By reducing the number of evaluations and aligning processes with global standards, producers can decrease compliance costs and allocate resources more effectively. The program not only streamlines the path to market but also enhances operational efficiency, as evidenced by the case study on the USFDA’s acceptance of its evaluation reports as substitutes for routine inspections.

    These advantages not only streamline operations but also position manufacturers competitively within the dynamic medical device landscape, ultimately enhancing their potential for growth and innovation.

    The central node represents the overall benefits of MDSAP, while each branch highlights a specific advantage. Follow the branches to explore how each benefit contributes to market access and operational efficiency.

    Overcome Common Challenges in MDSAP Audits

    Producers often encounter significant challenges during single audit program evaluations. Understanding these common issues and implementing effective strategies can greatly enhance .

    • : Inadequate documentation is a prevalent pitfall. To combat this, ensure that all records are complete, organized, and easily accessible. Establishing a robust document control system aids in efficiently managing changes and updates, significantly minimizing errors and improving adherence.
    • : Many organizations underestimate the critical role of training in compliance with regulations. It is essential for all team members to be well-informed about the requirements and their specific responsibilities. Regular training sessions not only reinforce this knowledge but also cultivate a culture of continuous improvement, vital for maintaining high standards of quality and safety. As noted, “,” underscoring its importance.

    Organizations may struggle if their . Conducting regular assessments and updates ensures that your QMS meets all essential requirements of MDSAP FDA, thereby enhancing readiness for evaluations and compliance.

    • : Promptly addressing nonconformities is crucial for successful evaluations. Implement a corrective action procedure that enables swift detection and resolution of problems before the evaluation, reducing potential disruptions.
    • : Maintaining open lines of communication with your auditing organization is essential. Clarifying expectations and seeking feedback throughout the preparation process can ensure alignment and enhance the overall evaluation experience.

    By proactively addressing these challenges, manufacturers can significantly improve their audit preparedness and increase their chances of meeting regulatory standards. Investing in comprehensive has been shown to reduce errors and defects in the manufacturing process, ultimately leading to higher-quality s and enhanced patient safety. For instance, a case study on “Reducing Errors and Defects” illustrates how targeted training initiatives can lead to substantial improvements in compliance and product quality.

    The center represents the main topic of overcoming audit challenges. Each branch shows a specific challenge, and the sub-branches detail strategies to address those challenges. This visual helps you see how to tackle each issue effectively.

    Conclusion

    Mastering MDSAP FDA compliance is not just essential; it’s a strategic imperative for medical device manufacturers seeking to enhance market access and operational efficiency. By grasping the intricate requirements of the MDSAP program – including the integration of ISO standards and local regulations – organizations can adeptly navigate the complexities of compliance. This foundational knowledge not only prepares them for successful audits but also positions them competitively within the global medical device landscape.

    Key strategies such as:

    1. Conducting gap analyses
    2. Providing targeted training
    3. Engaging with auditing organizations

    are vital for ensuring audit readiness. Addressing common challenges – like insufficient documentation and inadequate staff training – can significantly improve compliance outcomes. By adopting these best practices, manufacturers can streamline processes, reduce compliance costs, and ultimately enhance the quality and safety of their medical devices.

    The significance of MDSAP compliance extends beyond mere regulatory adherence; it represents a strategic advantage in a rapidly evolving market. Embracing these practices fosters a culture of continuous improvement and empowers manufacturers to seize opportunities for growth and innovation. As the global medical device market continues to expand, leveraging MDSAP effectively will be crucial for organizations aiming to thrive in this competitive environment.

    Frequently Asked Questions

    What is MDSAP and why is it important for manufacturers?

    MDSAP stands for the Medical Device Single Audit Program, which merges ISO 13485:2016 standards with the regulatory mandates of participating countries, including the USA, Canada, Brazil, Japan, and Australia. It is important for manufacturers to ensure compliance with these standards to facilitate market access and enhance operational efficiency.

    What are the key compliance requirements for MDSAP?

    Key compliance requirements for MDSAP include establishing a Quality Management System (QMS) aligned with ISO 13485 standards, implementing a risk management process in accordance with ISO 14971, staying updated on regulatory requirements of each participating country, and maintaining comprehensive documentation that demonstrates adherence to both ISO standards and local regulations.

    What is a Quality Management System (QMS) in the context of MDSAP?

    A Quality Management System (QMS) is a structured system that ensures all processes are documented and controlled, aligning with ISO 13485 standards. It helps organizations collect objective evidence of conformity and analyze trends to identify nonconformities.

    How should manufacturers approach risk management under MDSAP?

    Manufacturers should implement a risk management process that complies with ISO 14971, focusing on identifying, evaluating, and mitigating risks associated with medical devices. Integrating the QMS and Risk Management Systems (RMS) is essential for improving device designs and ensuring reliable supply chains.

    Are there different regulatory requirements for each participating country in MDSAP?

    Yes, regulatory requirements can vary significantly among participating countries. For example, in Canada, participation in the MDSAP program is mandatory for class II, III, and IV medical devices since January 1, 2019, while it remains optional in other countries.

    What types of documentation are necessary for MDSAP compliance?

    Necessary documentation for MDSAP compliance includes design history files, technical files, and clinical evaluation reports. Maintaining effective documentation practices is crucial, as auditors assess planning activities regarding purchased products and outsourced processes.

    What are potential pitfalls in compliance with MDSAP?

    Potential pitfalls include excessive reliance on risk tools without adequate understanding, which can lead to poor risk-based decisions. It is also important to enhance personnel competency standards to effectively manage compliance complexities.

    How can manufacturers better prepare for MDSAP audits?

    Manufacturers can better prepare for MDSAP audits by understanding the compliance requirements, maintaining comprehensive documentation, and integrating insights from specialists to enhance personnel competency and decision-making processes.

    List of Sources

    1. Understand MDSAP Compliance Requirements
      • nsf.org (https://nsf.org/life-science-regulatory-news/mdsap-audit-approach-update-what-changed-and-why-it-matters)
      • registrarcorp.com (https://registrarcorp.com/blog/medical-devices/iso-13485/measurement-analysis-improvement-in-medical-devices)
      • mddionline.com (https://mddionline.com/regulatory-quality/preparing-for-2026-mdsap-as-your-regulatory-compliance-guide)
      • thefdagroup.com (https://thefdagroup.com/blog/mdsap-audits)
    2. Implement Effective MDSAP Audit Preparation Strategies
      • nsf.org (https://nsf.org/life-science-regulatory-news/mdsap-audit-approach-update-what-changed-and-why-it-matters)
      • thefdagroup.com (https://thefdagroup.com/blog/mdsap-preparation)
    3. Leverage MDSAP for Strategic Market Access and Efficiency
      • sgs.com (https://sgs.com/en-au/news/2024/09/mdsap-unlocks-global-market-access-for-medical-device-manufacturers)
      • mdsap.global (https://mdsap.global/about/benefits-and-use)
      • sgs.com (https://sgs.com/en/news/2025/07/multi-market-access-with-mdsap)
      • biobostonconsulting.com (https://biobostonconsulting.com/unlocking-compliance-the-benefits-of-the-medical-device-single-audit-program-mdsap)
    4. Overcome Common Challenges in MDSAP Audits
      • nsf.org (https://nsf.org/life-science-regulatory-news/mdsap-audit-approach-update-what-changed-and-why-it-matters)
      • qualityze.com (https://qualityze.com/blogs/revolutionizing-training-to-ensure-superior-quality-safety-and-compliance-in-medical-device-manufacturing)
      • ropesgray.com (https://ropesgray.com/en/insights/alerts/2026/02/a-qmsr-state-of-mind-fda-adopts-new-inspection-approach-for-medical-devices)
      • rookqs.com (https://rookqs.com/blog-rqs/leveraging-mdsap-to-prepare-for-qmsr-integration)
      • compliancebridge.com (https://compliancebridge.com/4-quote-that-underscore-importance-of)

  • Master the FDA Priority Review Process: A Step-by-Step Guide

    Master the FDA Priority Review Process: A Step-by-Step Guide

    Introduction

    The FDA Priority Review process serves as a crucial lifeline for innovative therapies, aimed at expediting the approval of medications that tackle serious health conditions. By significantly reducing the review timeline from ten months to just six, this process not only enhances patient access to potentially life-saving treatments but also highlights the necessity of strategic planning in drug development.

    However, navigating this complex landscape presents challenges:

    1. What essential steps must companies take to ensure their applications meet the stringent criteria for priority review?
    2. Moreover, how can effective communication with the FDA influence the achievement of timely approvals?

    Understand the FDA Priority Review Process

    The procedure known as is a vital system created to hasten the assessment of medications that considerably improve the treatment of serious conditions. This designation facilitates an , allowing the FDA to process applications within six months, significantly reducing the standard ten-month review period. Such an expedited timeline is vital for therapies addressing unmet medical needs, allowing patients quicker access to potentially life-saving treatments.

    As of 2026, over 94% of medications that receive benefit from this , highlighting its critical role in . This procedure is particularly advantageous for medications that have received , with more than two-thirds of these also obtaining . A previous analysis revealed that 72% of treatments with from 2013 to 2022 were approved, underscoring the effectiveness of this expedited pathway.

    Recent examples illustrate the success of this process: between 2014 and 2022, all 48 treatments that received underwent , showcasing the FDA’s commitment to facilitating access to innovative therapies. Noteworthy medications that have benefited from include Achieve Life Sciences’ cytisinicline for nicotine dependence and GSK’s Jemperli for endometrial cancer, both of which were awarded the Commissioner’s National Priority Review Voucher, further emphasizing their significance.

    Understanding the and types of applications that qualify for is essential for strategic planning in . Familiarity with this process can greatly and overall development timelines, ultimately improving patient outcomes. As Jefferies analysts have noted, the regulatory framework at the FDA remains largely unchanged, highlighting the significance of in advancing .

    Follow the arrows to see how a medication moves through the FDA Priority Review process - from submission to approval and ultimately to patient access. Each step highlights the importance of this expedited pathway in bringing new treatments to those in need.

    Identify Eligibility Criteria for Priority Review

    To qualify for , a treatment must address a serious condition and demonstrate a compared to existing therapies. The FDA rigorously evaluates applications based on robust clinical data that substantiates these claims. Companies should be prepared to present persuasive evidence during the , including data from that clearly highlight the treatment’s advantages. Understanding the FDA’s specific definitions of ‘serious condition’ and ‘significant improvement‘ is crucial for aligning development efforts with regulatory expectations.

    Significantly, around 40% of medications approved from 2013 to 2022 were categorized as first-in-class, indicating a trend toward innovative therapies that meet these criteria. Recent FDA decisions reflect a commitment to expedited pathways, as 26% of novel treatment approvals were granted . This underscores the importance of strategic planning in the development process. At bioaccess, we recognize the urgency for startups; our , compliant with ICH-GCP standards, are designed to accelerate your submissions.

    With operations across Latin America, we ensure that you can present the compelling evidence needed to secure funding and navigate the effectively.

    Start at the center with the main eligibility criteria, then explore each branch to understand the specific requirements and supporting statistics that guide the FDA's review process.

    Prepare Your New Drug Application (NDA)

    is a critical step in the , requiring a meticulous compilation of extensive data that demonstrates the product’s safety and efficacy. include:

    1. Clinical Data: This encompasses results from Phase 1, 2, and 3 clinical trials, providing essential proof of the treatment’s effectiveness and safety profile. Statisticians conduct to confirm the reliability of these results. At bioaccess, we recognize the urgency faced by startups; our deliver the proof points necessary for successful fundraising and expedited FDA submissions.
    2. Manufacturing Information: Detailed descriptions of the medication’s production methods, adherence to Good Manufacturing Practices (GMP), quality control measures, and stability data are vital to ensure that the medication can be produced consistently and safely.
    3. Labeling: Proposed labeling must clearly outline indications, dosage, and administration guidelines, ensuring accuracy for healthcare providers and patients alike.
    4. : This outlines strategies for monitoring and mitigating potential risks associated with the drug, which is crucial for maintaining patient safety post-approval.
    5. : Engaging with the FDA prior to submission can clarify expectations and enhance the quality of the application. Performing a Pre-Submission Validation Check helps identify missing files or compliance issues, further optimizing the workflow.

    Companies must ensure that all sections of the NDA are meticulously prepared and aligned with . A well-structured NDA significantly increases the likelihood of , reducing the risk of delays or additional requests for information. Notably, the allows for a shortened evaluation timeline of 6 months for certain medications. As experts emphasize, “A well-prepared NDA submission is essential for a smooth FDA review, helping to prevent delays and requests for additional data.

    This flowchart outlines the essential steps for preparing an NDA. Each box represents a critical component of the application process. Follow the arrows to see how each part connects and the order in which they should be addressed.

    Communicate Effectively with the FDA

    Effective communication with the FDA is crucial for successfully navigating the . To enhance your interactions, consider these :

    1. : Schedule these meetings to discuss your and gather feedback on your data and submission strategy. Required documentation includes the product’s intended use statement and product labels. These meetings can lead to increased and reduce the number of deficiency cycles, making them a vital step in the approval process.
    2. : Meticulously document all communications. Prompt and comprehensive replies to FDA inquiries are essential for ensuring clarity and transparency during the evaluation.
    3. : Leverage available and resources to align your submission with regulatory expectations. This proactive approach can clarify objectives and optimize the evaluation process.
    4. Establish a : Designate a knowledgeable team member as the primary contact for FDA communications. This role is essential for streamlining interactions and ensuring that all inquiries are addressed efficiently.
    5. : Anticipate potential questions or concerns from the FDA and address them in your submission. This foresight can reduce delays and foster a cooperative relationship with the FDA, enabling smoother assessments and quicker resolutions to any issues.

    not only clarify regulatory pathways but also provide insights that can significantly impact the success of your submission, making them an indispensable part of the FDA priority review communication strategy.

    Follow the arrows to see each step you can take to improve your communication with the FDA. Each box highlights a key strategy, helping you navigate the approval process more effectively.

    Manage Post-Submission Interactions and Timelines

    After submitting your NDA for , managing interactions with the FDA is crucial for ensuring timely progress. Here are essential steps to effectively navigate this phase:

    1. Track Submission Status: Regularly check the status of your NDA through the FDA’s , which provides real-time updates on your application.
    2. : If the FDA requests additional information or clarification, respond as quickly as possible to avoid delays. Prompt replies are essential, as the average response duration for FDA inquiries can greatly influence your assessment timeline.
    3. Schedule Follow-Up Meetings: If necessary, arrange follow-up meetings with the FDA to discuss any outstanding issues or questions. These discussions can clarify expectations and facilitate smoother communication.
    4. Monitor Timelines: Keep track of the and be aware of the six-month goal for Priority Evaluation. Understanding these timelines aids you in anticipating important milestones in the process.
    5. Prepare for Potential Outcomes: Be ready for various outcomes, including approval, requests for additional data, or a (CRL). Familiarizing yourself with these possibilities allows for better planning of your next steps. Additionally, be aware that the FDA conducts ongoing inspections of manufacturing facilities to ensure compliance with (GMP) post-approval, which is vital for maintaining market access.
    6. Consider : Understand the importance of the FDA’s Sentinel Initiative, which tracks real-world adverse events and emerging safety concerns. This ongoing regulatory responsibility is crucial for ensuring the long-term safety and effectiveness of your medication.
    7. : Be mindful of labeling requirements, as deficiencies in labeling remain a leading cause of regulatory delays and rejection letters. Ensuring adherence to labeling standards can assist in reducing possible problems during the evaluation stage.

    By maintaining proactive communication and responsiveness, you can help ensure a smoother review process and potentially expedite the approval of your drug.

    Each box represents a crucial step in managing your NDA submission with the FDA. Follow the arrows to see the order of actions you should take to ensure a smooth review process.

    Conclusion

    In conclusion, the FDA Priority Review process stands as a vital mechanism that accelerates the approval of medications significantly enhancing the treatment of serious conditions. By mastering this process, pharmaceutical companies can ensure that innovative therapies reach patients more swiftly, addressing urgent medical needs effectively.

    This guide has outlined essential insights into the FDA Priority Review process, covering eligibility criteria, the preparation of a robust New Drug Application (NDA), and effective communication strategies with the FDA. It’s clear that meticulous planning and proactive engagement with regulatory bodies are crucial for maximizing the chances of securing priority review designation and achieving timely approval.

    As the drug development landscape evolves, the significance of the FDA Priority Review process remains paramount. Companies are encouraged to leverage the insights shared here to refine their application strategies and enhance communication with the FDA. By doing so, they not only improve their ability to bring life-saving treatments to market but also contribute to the overall advancement of healthcare.

    Frequently Asked Questions

    What is the FDA Priority Review process?

    The FDA Priority Review process is a system designed to expedite the assessment of medications that significantly improve the treatment of serious conditions, allowing the FDA to process applications within six months instead of the standard ten months.

    Why is the FDA Priority Review process important?

    This expedited timeline is crucial for therapies addressing unmet medical needs, as it allows patients quicker access to potentially life-saving treatments.

    What percentage of medications benefit from FDA Priority Review designation?

    As of 2026, over 94% of medications that receive FDA priority review designation benefit from this expedited treatment.

    How does the Priority Review process relate to breakthrough designation?

    The Priority Review process is particularly advantageous for medications with breakthrough designation, with more than two-thirds of these also obtaining FDA priority review and subsequent approval.

    What has been the approval rate for treatments with breakthrough designation from 2013 to 2022?

    A previous analysis revealed that 72% of treatments with breakthrough designation from 2013 to 2022 were approved.

    Can you provide examples of medications that have benefited from FDA Priority Review?

    Notable medications include Achieve Life Sciences’ cytisinicline for nicotine dependence and GSK’s Jemperli for endometrial cancer, both of which received the Commissioner’s National Priority Review Voucher.

    What are the eligibility criteria for FDA Priority Review?

    To qualify for FDA priority review, a treatment must address a serious condition and demonstrate a significant improvement in safety or effectiveness compared to existing therapies.

    What type of evidence is required for a New Medicine Application (NDA) submission?

    Companies must present robust clinical data that substantiates claims of safety and effectiveness, highlighting the treatment’s advantages.

    What trend has been observed regarding first-in-class medications from 2013 to 2022?

    Around 40% of medications approved during this period were categorized as first-in-class, indicating a trend towards innovative therapies that meet the criteria for priority review.

    How can companies prepare for the FDA Priority Review process?

    Companies should understand the FDA’s definitions of ‘serious condition’ and ‘significant improvement’ and be prepared to present compelling evidence during the NDA submission to align with regulatory expectations.

    List of Sources

    1. Understand the FDA Priority Review Process
      • biomedpharmajournal.org (https://biomedpharmajournal.org/vol18no3/a-comprehensive-review-of-us-fda-novel-drug-approvals-from-2013-2022-an-observational-study)
      • biospace.com (https://biospace.com/fda/fda-breakthrough-designations-lead-to-accelerated-reviews-report-finds)
      • fda.gov (https://fda.gov/drugs/office-prescription-drug-promotion/educational-case-studies)
    2. Identify Eligibility Criteria for Priority Review
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC9708961)
      • biomedpharmajournal.org (https://biomedpharmajournal.org/vol18no3/a-comprehensive-review-of-us-fda-novel-drug-approvals-from-2013-2022-an-observational-study)
    3. Prepare Your New Drug Application (NDA)
      • fda.gov (https://fda.gov/about-fda/histories-fda-regulated-products/summary-nda-approvals-receipts-1938-present)
      • excedr.com (https://excedr.com/blog/new-drug-application-process)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC9708961)
      • biomedpharmajournal.org (https://biomedpharmajournal.org/vol18no3/a-comprehensive-review-of-us-fda-novel-drug-approvals-from-2013-2022-an-observational-study)
    4. Communicate Effectively with the FDA
      • fdli.org (https://fdli.org/2017/12/value-fda-pre-submission-meetings-enhancements-pdufa-vi)
      • kapstonemedical.com (https://kapstonemedical.com/resource-center/blog/how-useful-are-pre-sub-meetings-with-fda)
      • statnews.com (https://statnews.com/2025/06/17/fda-new-priority-reviews-will-cut-months-off-drug-approvals)
      • thefdagroup.com (https://thefdagroup.com/blog/pre-ind-meeting)
    5. Manage Post-Submission Interactions and Timelines
      • excedr.com (https://excedr.com/blog/new-drug-application-process)
      • pharmaregulatory.in (https://pharmaregulatory.in/regulatory-case-studies-and-best-practices)

  • Radiopharmaceutical Trials In Latin America: A Practical Logistics Playbook For Short‑Lived Isotopes

    Radiopharmaceutical Trials in Latin America: A Practical Logistics Playbook for Short‑Lived Isotopes

    Radiopharmaceutical trials are a different operational species. The science may be the differentiator, but logistics is the constraint: short half-lives, radiation safety requirements, time-sensitive patient scheduling, and multi-agency approvals for cross-border movement. Sponsors who treat radiopharma like a conventional IMP supply chain often learn the hard way—through missed dosing windows and unusable shipments.

    1) Start with the physics: half-life turns every delay into lost dose

    If your isotope decays in hours, you don’t have “shipping delays”—you have immediate product shrinkage. The planning unit is not days; it is minutes. That means your protocol and operations plan must specify allowable time windows for production, release testing, transport, and administration, and it must include decision rules for when to cancel, reschedule, or reroute.

    • Define the decay budget: the maximum elapsed time from end of synthesis to administration.
    • Map critical control points: handoffs where delays occur (release, airport acceptance, customs, last-mile, site receiving).
    • Build a “go/no-go” clock: so everyone knows when continuing becomes scientifically meaningless.

    2) Cross-border execution in Latin America: permits, airports, and handoffs

    In many Latin America routes, the main risk is not distance—it is variability: airline handling, airport screening queues, and country-by-country documentation requirements. The most reliable programs treat each shipment like a rehearsed procedure rather than an ad hoc package drop.

    Internal execution experience across the region repeatedly highlights that reliability improves when sponsors standardize these elements:

    • Packaging qualification: validated temperature/containment performance and clear labeling for every handler.
    • Documentation kit: standardized set of shipping papers, permits, and emergency contacts—pre-reviewed by local experts.
    • Chain of custody: timestamped handoffs with escalation triggers.
    • Site receiving SOP: pre-briefed staff, equipment readiness, and immediate QC/receipt checks.

    3) Site readiness: the hidden bottleneck

    Even a perfect shipment fails if the site is not ready. A radiopharma site must coordinate pharmacy/nuclear medicine teams, imaging, patient prep, and administration windows. The sponsor’s job is to make this coordination easy and repeatable.

    Recommended site readiness checklist:

    • Weekly capacity confirmation: confirm patient slots, staff coverage, and scanner availability.
    • Receiving drill: simulate the shipment arrival, handoff, and documentation review.
    • Waste and incident plan: clear procedures for contamination, spills, and disposal aligned with local requirements.
    • Back-up scheduling: a pre-identified alternative window when a shipment is delayed but still usable.

    4) Resilience without runaway cost: design a tiered contingency plan

    Not every shipment needs the most expensive option. Create a tiered plan:

    • Tier 1 (default): primary carrier + primary route, with standard packaging and standard site workflow.
    • Tier 2 (moderate disruption): alternate flight routings and a backup last-mile provider.
    • Tier 3 (critical disruption): rapid escalation options, including premium routing and emergency re-release windows.

    This structure helps you maintain reliability while containing cost—and it makes decision-making faster in the moment.

    FAQ

    Why is radiopharma logistics harder than standard drug trials?
    Because many isotopes decay quickly, small delays in production, packaging, flight connections, or site preparation can reduce delivered activity and impact dosing windows.

    What is the most common operational failure mode?
    Misaligned schedules across cyclotron/production, export/import clearances, airport handling, last-mile transport, and site readiness—creating avoidable holds that consume half-life.

    How do sponsors add resilience without exploding cost?
    Use a tiered contingency plan: alternate flight routings, backup depots, standardized packaging, qualified second-source carriers, and rehearsed site receiving checklists; reserve higher-cost options only for critical shipments.

    Need help executing radiopharma studies in Latin America? bioaccess® supports sponsors with regional operational planning, site activation support, and logistics coordination built for time-sensitive programs.

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • Best Practices for CROs in Latin America: First-in-Human Trials

    Best Practices for CROs in Latin America: First-in-Human Trials

    Introduction

    In the rapidly evolving landscape of clinical research, particularly in Latin America, the role of Contract Research Organizations (CROs) is more critical than ever. As biopharma startups navigate the complexities of first-in-human trials, understanding effective collaboration, regulatory navigation, and site selection can significantly enhance their chances of success.

    However, with numerous challenges – from regulatory hurdles to funding alignment – how can CROs streamline processes and maximize outcomes? This article explores essential strategies that foster efficient partnerships and ensure clinical trials are executed smoothly and successfully in this dynamic region.

    Leverage Speed and Efficiency in CRO Collaboration

    To maximize the effectiveness of , establishing clear communication channels and setting mutual expectations from the outset is crucial. This involves defining roles, responsibilities, and timelines to ensure alignment among all parties. Project management tools can facilitate real-time updates and foster transparency, making the collaboration process more efficient.

    CROs should also adopt that allow for rapid adjustments in response to evolving project needs. For example, implementing regular check-ins can help identify potential bottlenecks early, enabling teams to address issues proactively. A compelling case study involving a startup that utilized bioaccess®‘s illustrates this point: by streamlining communication and adopting agile practices, the was reduced by 30%, allowing the company to secure additional funding ahead of schedule.

    This approach not only accelerates medical development but also enhances startups’ ability to connect with investors and strategic partners effectively. In the fast-paced landscape, collaboration is not just beneficial; it is essential for success.

    Follow the arrows to see how each step contributes to effective collaboration. Each box represents a key action or principle that enhances the partnership between CROs and startups.

    Navigating the is crucial for CROs, as they must be acutely aware of the specific requirements in each country involved in research studies. In Brazil, significant reforms have streamlined the , cutting the average timeline from several months to as little as 30 business days. This improvement is part of a broader initiative aimed at enhancing the efficiency of medical research in the region, with . As Paulo Cesar Fernandes Jr. notes, “With the full implementation of the new law, key hurdles, such as the requirement for double ethical approvals, will have finally been removed.”

    To effectively manage these changes, CROs should early in the process to clarify expectations and requirements. , which can vary significantly across Latin America. Bioaccess’s offers essential research insights and market access strategies that assist CROs in creating a . This proactive approach not only facilitates smoother approvals but also enhances the overall .

    Specific strategies from include tailored guidance on and leveraging data to anticipate potential challenges. This ensures that CROs are well-prepared for the complexities of the regulatory landscape.

    The central node represents the main theme, while branches show different aspects of regulatory requirements and strategies. Follow the branches to explore how each area contributes to successful trials.

    Optimize Clinical Trial Site Selection for Enhanced Outcomes

    Choosing requires a strategic approach that considers patient demographics, location capabilities, and historical performance. This is crucial in the realm of , where the right site can significantly impact study outcomes. should focus on sites with a proven track record of .

    in this process, enhancing location selection by pinpointing areas with high concentrations of eligible patients. For example, a recent study in Colombia demonstrated a when selecting sites with established networks and skilled personnel. This statistic underscores the importance of informed decision-making in .

    Moreover, fostering can streamline operations and boost recruitment rates. Consistently evaluating is essential for making informed choices about site viability throughout the study. This ensures that the selected locations are well-equipped to deliver and meet study objectives effectively.

    The center represents the main focus of site selection, while the branches show the important factors to consider. Each branch can be explored for more details, helping you understand how each aspect contributes to successful clinical trials.

    Align Clinical Trial Timelines with Funding Cycles

    Aligning clinical study schedules with is crucial for aiming to optimize resources and ensure . A comprehensive project plan that incorporates is essential. This involves recognizing key capital rounds and strategically planning test activities to coincide with these financial inflows. For instance, one biopharma startup effectively coordinated its testing phases with investment rounds by adopting a staged approach to execution. This strategy enabled them to secure additional financial support based on positive interim results, showcasing the power of .

    Regular are vital for maintaining this alignment, ensuring that projects progress as intended and meet the necessary milestones for ongoing funding. However, it’s important to acknowledge that around 80% of encounter delays or closures due to , highlighting the necessity for meticulous planning. As market research analyst Samruddhi Yardi noted, ” are the linchpin of medical progress,” underscoring their critical role in advancing healthcare. By proactively addressing common pitfalls and challenges, can significantly enhance their chances of successfully aligning with funding cycles.

    Each box represents a step in the process of aligning clinical trials with funding. Follow the arrows to see how each step connects and leads to the next, ensuring a smooth execution of clinical studies.

    Conclusion

    Effective collaboration between Contract Research Organizations (CROs) and biopharma startups in Latin America is crucial for the success of first-in-human trials. By prioritizing speed and efficiency, CROs can significantly enhance the development process, ensuring that projects are completed on time and within budget. This collaborative approach not only accelerates medical advancements but also strengthens the connection between startups and potential investors.

    The article highlights several best practices for CROs, including:

    1. Establishing clear communication
    2. Navigating regulatory landscapes
    3. Optimizing clinical trial site selection
    4. Aligning trial timelines with funding cycles

    Each of these elements plays a vital role in ensuring that trials proceed smoothly and efficiently. By adopting agile methodologies, engaging with local regulatory bodies, utilizing data analytics for site selection, and strategically planning timelines, CROs can mitigate common challenges and drive successful outcomes.

    In conclusion, as the landscape of clinical trials in Latin America continues to evolve, embracing these best practices will be essential for CROs aiming to lead in first-in-human studies. The integration of efficient collaboration strategies, regulatory navigation, and informed site selection can significantly impact trial success rates. By fostering these practices, stakeholders can not only enhance the efficacy of their clinical trials but also contribute to the broader goal of advancing healthcare innovation in the region.

    Frequently Asked Questions

    What is the importance of establishing clear communication channels in CRO collaborations?

    Establishing clear communication channels is crucial for maximizing the effectiveness of CRO collaborations. It helps in setting mutual expectations, defining roles, responsibilities, and timelines to ensure alignment among all parties involved.

    How can project management tools assist in CRO collaborations?

    Project management tools facilitate real-time updates and foster transparency, making the collaboration process more efficient by keeping all parties informed and aligned on project progress.

    What methodologies should CROs adopt for effective collaboration?

    CROs should adopt agile methodologies that allow for rapid adjustments in response to evolving project needs. This includes implementing regular check-ins to identify potential bottlenecks early and address issues proactively.

    Can you provide an example of a successful CRO collaboration?

    A compelling case study involves a MedTech startup that utilized bioaccess®’s Innovation Runway. By streamlining communication and adopting agile practices, the testing timeline was reduced by 30%, enabling the company to secure additional funding ahead of schedule.

    How does effective collaboration impact medical development in startups?

    Effective collaboration accelerates medical development and enhances startups’ ability to connect with investors and strategic partners, which is essential for success in the fast-paced MedTech landscape.

    List of Sources

    1. Navigate Regulatory Requirements for Successful Trials
      • clinicalleader.com (https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001)
      • psi-cro.com (https://psi-cro.com/brazil-new-clinical-research-law)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC7704494)
      • insights.figlobal.com (https://insights.figlobal.com/regulations/understanding-the-regulatory-complexities-of-latin-america-interview-)
      • A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems – PubMed (https://pubmed.ncbi.nlm.nih.gov/40155114)
    2. Optimize Clinical Trial Site Selection for Enhanced Outcomes
      • clinicalleader.com (https://clinicalleader.com/doc/a-data-driven-approach-to-clinical-trial-site-selection-0001)
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC10927105)
      • Data-Driven Approach to Clinical Trial Site Selection | Signant Health (https://signanthealth.com/resources/blog/a-data-driven-approach-to-clinical-trial-site-selection-signant-health)
      • The Transformative Power of Data Analytics in Clinical Trials | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/the-transformative-power-of-data-analytics-in-clinical-trials)
    3. Align Clinical Trial Timelines with Funding Cycles
      • Clinical Trials Statistics By Phases, Definition and Interventions (2026) (https://media.market.us/clinical-trials-statistics)
      • What clinical trial statistics tell us about the state of research today (https://antidote.me/blog/what-clinical-trial-statistics-tell-us-about-the-state-of-research-today)
      • blog.td2inc.com (https://blog.td2inc.com/quantifying-the-financial-impact-of-inefficient-clinical-trial-start-up)
      • statista.com (https://statista.com/statistics/1419920/biopharma-clinical-trial-cycle-time?srsltid=AfmBOoqnCXRXtscnfJZhJPQdTM5HEeddVTEw68dXMJtrvkFrEs380JH7)
      • intuitionlabs.ai (https://intuitionlabs.ai/articles/clinical-trial-delays-phase-i-iii)

  • 4 Key Strategies for Medical Device Startup Clinical Trials

    4 Key Strategies for Medical Device Startup Clinical Trials

    Introduction

    The landscape of medical device development presents significant challenges, especially in conducting clinical trials that adhere to regulatory standards and prioritize patient safety. For startups navigating this intricate terrain, grasping and implementing effective strategies can mean the difference between success and failure. This article delves into four essential strategies that not only streamline the clinical trial process but also boost the chances of regulatory approval and enhance patient engagement.

    How can startups harness:

    1. Early regulatory engagement
    2. Efficient protocol design
    3. Advanced technology
    4. Optimized recruitment

    to turn their clinical trials into successful ventures?

    Engage Early with Regulatory Authorities

    Startups must engage with as soon as they have a clear concept of their medical device. This early interaction not only facilitates valuable feedback on the proposed and regulatory pathway but also helps identify potential issues before they escalate. Companies that participate in often clarify and receive guidance on the necessary data to support their submissions. This proactive accelerates the and fosters a , which can be advantageous throughout the testing phases.

    Studies indicate that utilizing can lead to and fewer deficiency cycles, underscoring their essential role in the research landscape. Given that 90% of healthcare new ventures fail due to exhausting funds before producing required research data, is crucial. Bioaccess®’s Innovation Runway exemplifies this approach by offering a development pathway specifically tailored for , enabling MedTech, Biopharma, and Radiopharma new ventures to achieve milestones 40% quicker.

    A case study involving a MedTech company that engaged with the FDA early in its development process illustrates how adopting a resulted in a smoother approval timeline and reduced costs associated with regulatory compliance. Furthermore, bioaccess® provides Global Trial Accelerators™, delivering vital research insights and market entry strategies customized for startups in Latin America, ensuring they are well-prepared to navigate the regulatory environment efficiently.

    Each box represents a step in the engagement process with regulatory bodies. Follow the arrows to see how early engagement leads to feedback, clarification, and ultimately a smoother approval process.

    Design Efficient Clinical Trial Protocols

    A well-organized is essential for outlining research objectives, methodologies, and statistical analysis plans as part of the . Startups must prioritize developing flexible protocols that can adapt based on interim outcomes as part of their . This adaptability allows for prompt modifications that enhance efficiency. Current trends in are particularly advantageous as they align with a , enabling multiple studies to be conducted under a single overarching framework, which significantly saves time and resources. For instance, a recent utilized a that successfully executed a master protocol for their device testing, facilitating concurrent studies that expedited information collection and analysis.

    Moreover, integrating during the protocol design stage not only promotes participant involvement but also enhances retention rates, which is essential for a successful , ultimately leading to more positive study outcomes. This approach aligns with the growing recognition of the need for , particularly within a , ensuring that protocols can effectively respond to new information and participant requirements. Furthermore, utilizing provides emerging companies with vital insights and tailored strategies that strengthen their , a crucial element for generating authentic human clinical information essential for effective fundraising.

    By fostering an organizational culture that emphasizes cooperation, responsibility, and transparency among stakeholders, startups can further enhance their and improve testing efficiency. Clear communication of study objectives and maintaining open dialogue with investigators are essential elements of a to ensure that protocols are prioritized and executed effectively. It is also critical to address potential challenges, such as unclear eligibility criteria, which can lead to confusion and inconsistent information gathering. Proactive risk management and governance are essential to ensure efficient , thereby reinforcing the adaptability and effectiveness of the .

    The central node represents the main focus of the discussion. Each branch highlights a critical aspect of designing clinical trial protocols, showing how they relate to the overall strategy for medical device startups.

    Integrate Advanced Technology Solutions

    Startups must embrace – to significantly boost efficiency in . , for instance, facilitate real-time information collection and monitoring, easing participant burdens while enhancing accuracy. Take the Apple Heart Study, which involved over 400,000 participants and demonstrated that . This underscores their potential to improve both study accessibility and efficiency.

    A MedTech firm that integrated wearables into their research saw a remarkable increase in information collection efficiency and participant compliance. Furthermore, leveraging artificial intelligence (AI) for data analysis can expedite the identification of trends and results, leading to quicker decision-making. , further supporting effective management of experiments.

    By adopting these advanced solutions, new ventures can streamline operations and elevate the overall patient experience, ultimately paving the way for a more successful . Additionally, insights from provide crucial regulatory updates and in Latin America. However, it’s vital to address potential challenges, such as . Bioaccess tackles these through comprehensive support and guidance, ensuring the effective integration of these technologies.

    The central node represents the main theme of integrating technology. Each branch shows different aspects, like specific technologies and their benefits or challenges. Follow the branches to explore how these elements connect and contribute to improving clinical studies.

    Optimize Patient Recruitment Strategies

    To enhance , new companies must adopt a multifaceted strategy that leverages digital marketing, engages healthcare providers, and collaborates with . Focused outreach initiatives that connect with prospective participants can significantly boost awareness and interest in . For example, a startup that partnered with local healthcare providers saw a remarkable . Streamlining the enrollment process and clearly conveying the advantages of the study can alleviate concerns among potential participants.

    Moreover, utilizing to identify and target specific patient groups can strengthen recruitment efforts, ensuring that studies are sufficiently powered to yield valid and reliable outcomes. As digital marketing continues to evolve, its role in participant recruitment becomes increasingly vital. Insights from healthcare marketing experts highlight the effectiveness of customized digital campaigns in reaching diverse patient groups. It’s also crucial to note that , underscoring the financial implications of recruitment challenges.

    Furthermore, around 30 to 40 percent of enrolled research participants either withdraw or become notably non-compliant before the study reaches its primary endpoint. This statistic emphasizes the importance of alongside recruitment efforts. With nearly 80% of facing delays or closures due to , implementing effective strategies is essential for success.

    The center shows the main goal of optimizing patient recruitment, while the branches represent different strategies and their specific actions or outcomes. Follow the branches to see how each strategy contributes to the overall goal.

    Conclusion

    Engaging in clinical trials for medical devices presents unique challenges and opportunities for startups. By implementing strategic approaches – such as early engagement with regulatory authorities, efficient protocol design, advanced technology integration, and optimized patient recruitment – startups can significantly enhance their chances of success in a competitive landscape.

    Proactive communication with regulatory bodies is crucial; it can lead to smoother approval processes and reduced costs. Moreover, developing adaptable clinical trial protocols allows for flexibility in response to real-time data and participant feedback, ultimately improving study outcomes. Embracing innovative technologies, like wearables and AI, streamlines operations and elevates the patient experience. Effective recruitment strategies ensure that trials are adequately powered and participant retention is maximized.

    The significance of these strategies cannot be overstated. They not only contribute to the success of individual trials but also shape the future of medical device innovation. Startups are strongly encouraged to adopt these best practices to navigate the complexities of clinical trials effectively. By doing so, they can improve their own outcomes and contribute to advancements in healthcare that benefit society as a whole.

    Frequently Asked Questions

    Why is it important for startups to engage early with regulatory authorities?

    Early engagement with regulatory bodies like the FDA or EMA allows startups to receive valuable feedback on their clinical study design and regulatory pathway, helping to identify potential issues before they escalate.

    What benefits do pre-submission meetings provide for startups?

    Pre-submission meetings clarify regulatory expectations, offer guidance on the necessary data for submissions, and can lead to higher first-cycle clearance rates and fewer deficiency cycles.

    How does early interaction with regulators impact the approval process?

    Proactive engagement accelerates the approval process and fosters positive relationships with regulators, which can be beneficial throughout the testing phases.

    What role does Bioaccess®’s Innovation Runway play in supporting startups?

    Bioaccess®’s Innovation Runway offers a development pathway tailored for First-in-Human experiments, helping MedTech, Biopharma, and Radiopharma ventures achieve milestones 40% quicker.

    Can you provide an example of a successful early engagement with the FDA?

    A case study showed that a MedTech company that engaged with the FDA early in its development process experienced a smoother approval timeline and reduced costs related to regulatory compliance.

    What services does Bioaccess® provide to startups in Latin America?

    Bioaccess® offers Global Trial Accelerators™, which deliver essential research insights and market entry strategies customized for startups, helping them navigate the regulatory environment efficiently.

    List of Sources

    1. Engage Early with Regulatory Authorities
      • fdli.org (https://fdli.org/2017/12/value-fda-pre-submission-meetings-enhancements-pdufa-vi)
      • kapstonemedical.com (https://kapstonemedical.com/resource-center/blog/how-useful-are-pre-sub-meetings-with-fda)
      • worldwide.com (https://worldwide.com/blog/2024/06/early-ongoing-regulatory-engagement-for-successful-clinical-trials)
    2. Design Efficient Clinical Trial Protocols
      • allucent.com (https://allucent.com/resources/blog/best-practices-clinical-study-protocol-writing)
      • Clinical Trial Protocol Development Best Practices for Success (https://comac-medical.com/clinical-trial-protocol-development-best-practices-for-success)
      • Improving Study Start-Up Efficiency to Accelerate the Clinical Trial Timeline – ACRP (https://acrpnet.org/2026/02/17/improving-study-start-up-efficiency-to-accelerate-the-clinical-trial-timeline)
      • clinicaltrialrisk.org (https://clinicaltrialrisk.org/clinical-trial-design/protocol-design-for-clinical-trials-the-complete-checklist)
    3. Integrate Advanced Technology Solutions
      • clinaudits.com (https://clinaudits.com/case-studies-and-real-world-applications-of-wearables-in-clinical-trials)
      • Top Five Health Care Trends for 2026: How New Technology Is Transforming Patient Care (https://aanp.org/news-feed/top-five-health-care-trends-for-2026-how-new-technology-is-transforming-patient-care)
      • informaconnect.com (https://informaconnect.com/wearables-clinical-trials-case-studies)
      • subjectwell.com (https://subjectwell.com/digital-health-clinical-trials)
      • crucialdatasolutions.com (https://crucialdatasolutions.com/blog/future-of-wearable-technology-clinical-trials)
    4. Optimize Patient Recruitment Strategies
      • Patient Engagement Quotes: For Every Purpose & Audience (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)
      • Clinical studies: the challenge of patient recruitment (https://servier.com/en/newsroom/clinical-studies-patient-recruitment)
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • Enrollment in Clinical Trials: Statistics and Patient Recruitment Strategies | Power (https://withpower.com/guides/enrollment-in-clinical-trials-statistics-and-patient-recruitment-strategies)

  • Navigate Regulatory Pathways for Medical Devices in Latin America

    Navigate Regulatory Pathways for Medical Devices in Latin America

    Introduction

    Navigating the complex regulatory pathways for medical devices in Latin America is crucial for any company looking to succeed in the region’s rapidly growing healthcare market. With a variety of regulations overseen by key authorities such as:

    1. ANVISA in Brazil
    2. COFEPRIS in Mexico
    3. INVIMA in Colombia

    Grasping the specific requirements can greatly influence a product’s success. As regulatory landscapes evolve and align with international standards, businesses must confront the challenge of keeping up with these changes. How can companies effectively navigate this intricate environment to ensure compliance and secure successful market entry?

    Understand the Regulatory Landscape in Latin America

    Navigating the is crucial for success in . A thorough understanding of the is essential, particularly the . Each agency has distinct regulations, guidelines, and approval procedures that must be meticulously adhered to. Knowing the is vital for anticipating challenges and simplifying your submission process.

    To effectively understand the , consider these steps:

    1. Research Oversight Authorities: Identify the primary overseeing bodies in your target countries and grasp their specific functions.
    2. : Familiarize yourself with the laws and regulations governing healthcare instruments in each country, including recent updates that may influence your submissions.
    3. Stay Updated on Changes: ; subscribing to updates from relevant agencies ensures you remain informed about new regulations or amendments.
    4. : Consulting with local regulatory professionals or firms specializing in the registration of health-related products can provide valuable insights into the nuances of each market, enhancing your chances of successful navigation.

    As of February 2026, ANVISA has implemented , aligning more closely with international standards. COFEPRIS continues to refine its regulations, focusing on enhancing patient safety and compliance. INVIMA is also actively updating its frameworks to enable quicker market access for innovative health products. Understanding these updates is essential for in the context of .

    The center represents the main topic, while branches show key authorities and steps to navigate the regulatory environment. Each color-coded branch helps you see how different elements connect to the central theme.

    Identify Country-Specific Registration Requirements

    Once you grasp the regulatory landscape, particularly the role of , the next step is to pinpoint the specific . INVIMA oversees the promotion and production of health products in Colombia and is recognized as a Level 4 health authority by PAHO/WHO, ensuring the safety, efficacy, and quality of . This involves understanding the categorization, documentation, and submission procedures for your healthcare apparatus.

    Steps to Identify Registration Requirements:

    1. Classify Your Device: Determine the (Class I, II, or III) as this will dictate the oversight pathway.
    2. : Compile all necessary documents, including technical files, clinical data, and labeling information, tailored to each country’s requirements.
    3. Understand : Familiarize yourself with the , including timelines and fees.
    4. Consult Regulatory Guidelines: Review the , including INVIMA, to ensure compliance with their requirements.
    5. Utilize Resources: Leverage online materials and databases that offer current information on in Latin America.

    As we look ahead to 2026, the categorization of in Latin America continues to evolve, emphasizing the need for among nations. For instance, Brazil’s ANVISA and Mexico’s COFEPRIS have established clear classification systems that can serve as models for other countries. Understanding the not only supports compliance but also enhances your competitive edge in the rapidly growing healthcare equipment market.

    Each box represents a step you need to take to ensure your medical device meets registration requirements. Follow the arrows to see how each step leads to the next in the process.

    Prepare Required Documentation for Submission

    Preparing the necessary documentation for registration in is not just essential; it’s a critical step for compliance and successful market entry. This documentation must be thorough and align with the specific guidelines established by local regulatory authorities.

    1. Compile : Start by gathering detailed equipment specifications, manufacturing processes, and quality control measures. This information is crucial for demonstrating adherence to , often regarded as the ‘gold standard’ for quality management in the medical equipment sector.
    2. Include : Present robust clinical data that substantiates the safety and efficacy of your device. This should encompass outcomes from , as oversight organizations increasingly emphasize the importance of in the approval process. For example, in Mexico, the allows for a 30-day approval for healthcare products with existing FDA or CE certifications, underscoring the value of prior clinical validation.
    3. Ensure Compliance with Local Language Requirements: All documentation must be translated into the official language of the country where the submission is made. This step is crucial to prevent delays in processing and to ensure that all compliance requirements are met.
    4. Create a : Organize all documents into a coherent dossier that complies with the format required by the governing body. The is widely recognized and can facilitate smoother submissions across different jurisdictions.
    5. Review and Revise: Conduct a meticulous review of all documents to ensure accuracy and completeness before submission. Involving can deepen your understanding of specific requirements and significantly increase the likelihood of successful approval.

    By adhering to these steps, manufacturers can navigate the regulatory pathways for medical devices in Latin America, ensuring compliance and accelerating market entry.

    Each box represents a crucial step in the documentation process. Follow the arrows to see how to move from one step to the next, ensuring all requirements are met for successful submission.

    Implement Post-Market Surveillance Strategies

    After successfully obtaining regulatory approval for your medical product, it is crucial to understand the and implement robust . This ensures that the equipment continues to meet throughout its lifecycle, especially under the oversight of , which plays a vital role in and navigating the .

    Steps to Implement Post-Market Surveillance:

    • Establish a Monitoring System: Create a system for collecting and analyzing data on equipment performance and .
    • Conduct Regular Reviews: Schedule periodic reviews of post-market data to identify trends or issues that may arise.
    • Engage with : Foster relationships with healthcare providers to gather feedback on product performance in real-world settings.
    • Report : Ensure there is a clear process for reporting any to the governing authorities, including INVIMA.
    • Update Oversight Agencies: Keep oversight bodies informed of any significant findings or changes in the device’s risk profile.

    With experts like Ana Criado, who has extensive experience in and the support of INVIMA’s , companies can effectively navigate these .

    Each box represents a crucial step in the process of monitoring medical devices after they hit the market. Follow the arrows to see how each step builds on the previous one, ensuring safety and compliance.

    Conclusion

    Navigating the regulatory pathways for medical devices in Latin America is not just essential; it’s a critical factor for successful market entry and compliance. A comprehensive understanding of the regulatory landscape – including the roles of key authorities such as ANVISA, COFEPRIS, and INVIMA – enables companies to anticipate challenges and streamline their submission processes. By grasping the specific requirements of each country, businesses can effectively position themselves for success in this dynamic market.

    This article outlines the critical steps for navigating these pathways:

    1. Research oversight authorities to understand their influence.
    2. Identify country-specific registration requirements to ensure compliance.
    3. Prepare thorough documentation that meets these standards.
    4. Implement robust post-market surveillance strategies to maintain safety and efficacy throughout the device lifecycle.

    Each of these elements plays a pivotal role in ensuring that medical devices not only meet regulatory standards but also uphold their safety and effectiveness. Staying informed about regulatory updates and engaging with local specialists further enhances the likelihood of successful navigation.

    In conclusion, the significance of understanding and adhering to the regulatory pathways for medical devices in Latin America cannot be overstated. Companies must prioritize compliance and proactive engagement with regulatory authorities to thrive in this competitive landscape. Embracing these strategies will facilitate smoother market entry and contribute to the ongoing safety and effectiveness of medical devices, ultimately benefiting healthcare providers and patients alike.

    Frequently Asked Questions

    Why is understanding the regulatory landscape in Latin America important for medical devices?

    Understanding the regulatory landscape is crucial for success in clinical research and product promotion, as each country has distinct regulations and approval procedures that must be followed.

    Which key authorities oversee medical device regulations in Latin America?

    The primary authorities include ANVISA in Brazil, COFEPRIS in Mexico, and INVIMA in Colombia.

    What steps should be taken to navigate the regulatory landscape effectively?

    Key steps include researching oversight authorities, reviewing regulatory frameworks, staying updated on changes, and engaging with local specialists.

    How can one stay informed about regulatory changes in Latin America?

    Subscribing to updates from relevant regulatory agencies can help ensure you are informed about new regulations or amendments.

    What recent updates have been made by ANVISA, COFEPRIS, and INVIMA?

    As of February 2026, ANVISA has streamlined its approval process to align with international standards, COFEPRIS is refining regulations to enhance patient safety, and INVIMA is updating its frameworks for quicker market access for innovative health products.

    Why is it important to consult with local regulatory professionals?

    Consulting with local specialists provides valuable insights into the nuances of each market, which can enhance the chances of successful navigation through the regulatory pathways.

    List of Sources

    1. Understand the Regulatory Landscape in Latin America
      • emergobyul.com (https://emergobyul.com/news/brazil-anvisa-announces-priorities-2026-2027-year)
      • marketdataforecast.com (https://marketdataforecast.com/market-reports/latin-america -implantable-medical-devices-market)
      • emergobyul.com (https://emergobyul.com/news/towards-global-medical-device-regulatory-alignment-changes-latin-american-markets)
      • 7 Medical Device Regulatory Trends 2025 LATAM You Need to Know | bioaccess® (https://bioaccessla.com/blog/7-medical-device-regulatory-trends-2025-latam-you-need-to-know)
      • complianceonline.com (https://complianceonline.com/resources/latin-america-market-entry-strategies-for-medical-device-companies.html)
    2. Identify Country-Specific Registration Requirements
      • marketdataforecast.com (https://marketdataforecast.com/market-reports/latin-america-medical-devices-market)
      • operonstrategist.com (https://operonstrategist.com/medical-device-registration-in-latam-countries)
      • chameleon-pharma.com (https://chameleon-pharma.com/navigating-the-regulatory-landscape-for-medical-device-registration-in-the-eu-and-latin-america)
      • emergobyul.com (https://emergobyul.com/resources/mexico-overview-medical-device-industry-and-healthcare-statistics)
      • mddionline.com (https://mddionline.com/regulatory-quality/latin-american-medical-device-regulations)
    3. Prepare Required Documentation for Submission
      • bioaccessla.com (https://bioaccessla.com/es/blog/10-key-latin-america-medical-device-standards-you-must-know)
      • emergobyul.com (https://emergobyul.com/services/cofepris-medical-device-and-ivd-registration-and-approval-mexico)
      • 6 Important Quotes from Medtech Leaders (https://mddionline.com/business/6-important-quotes-from-medtech-leaders)
      • latampharmara.com (https://latampharmara.com/fundamentals-of-regulatory-affairs/the-submission-dossier)
      • 7 quotes from 2023 to guide you on the medtech market (https://tiinatyni.com/blogi/7-quotes-from-2023-to-guide-you-on-the-medtech-market)
    4. Implement Post-Market Surveillance Strategies
      • psnet.ahrq.gov (https://psnet.ahrq.gov/issue/prevalence-adverse-events-hospitals-five-latin-american-countries-results-iberoamerican-study)
      • klara.com (https://klara.com/blog/12-best-quotes-on-the-future-of-healthcare)
      • 30 Quotes About the Future of Healthcare: Expert Takes (https://deliberatedirections.com/quotes-future-of-healthcare)
      • 10 Patient Experience Quotes for Inspiration (https://carecloud.com/continuum/patient-experience-quotes-for-inspiration)
      • 20 hospital execs’ most thought-provoking quotes on health IT in 2021 – Becker’s Hospital Review | Healthcare News & Analysis (https://beckershospitalreview.com/healthcare-information-technology/innovation/20-hospital-execs-most-thought-provoking-quotes-on-health-it-in-2021)

  • In Vivo vs In Vitro: Key Comparisons for Clinical Research Success

    In Vivo vs In Vitro: Key Comparisons for Clinical Research Success

    Introduction

    The distinction between in vivo and in vitro methodologies is foundational in clinical research, significantly influencing how scientists approach drug development and testing. Each method offers its own advantages and challenges, shaping the landscape of medical discovery. As researchers navigate the complexities of biological interactions, a critical question emerges: how can integrating these two approaches enhance the reliability and applicability of research outcomes?

    Exploring this comparison not only illuminates their unique roles but also uncovers the potential for a synergistic strategy that could revolutionize clinical practices. By understanding the strengths of both methodologies, we can pave the way for more effective and innovative solutions in the field.

    Define In Vivo and In Vitro: Key Concepts in Clinical Research

    The terms invivo vs in vitro are Latin phrases that define two essential methods of scientific research in living organisms. ‘In the living,’ indicating ‘within the living,’ pertains to research carried out inside a living organism, such as animal models or . This method allows researchers to observe biological processes in their natural context, yielding insights into complex interactions within tissues and systems. Experiments conducted within living organisms are crucial for assessing , as they demonstrate how therapies engage with various biological systems. At bioaccess, we offer comprehensive , including feasibility assessments and site selection, to ensure that is conducted effectively and ethically.

    Conversely, in glass, which translates to ‘in glass,’ involves experiments conducted outside of living organisms, typically in controlled laboratory environments like petri dishes or test tubes. This approach allows researchers to isolate specific variables and examine cellular mechanisms in detail, often resulting in quicker outcomes and fewer ethical concerns related to animal testing. are especially beneficial in initial research, enabling quick evaluation of substances and recognition of potential candidates prior to progressing to more intricate in vivo trials. Our services also include compliance reviews and trial setup, ensuring that laboratory studies meet regulatory standards.

    The comparison of invivo vs is indispensable in advancing medical knowledge and drug development, as each offers unique advantages and limitations. Recent trends suggest an increasing dependence on for initial testing, with around 70% of clinical trials incorporating in situ methods as they advance. Understanding the is crucial for assessing scientific discoveries and their implications for clinical practice. At bioaccess, we are committed to supporting researchers through every step of this process.

    The central node represents the comparison of the two research methods. Each branch shows key aspects of either in vivo or in vitro research, helping you understand their unique characteristics and how they relate to clinical research.

    Explore Applications: In Vivo vs. In Vitro in Clinical Research

    Experiments conducted within living organisms are pivotal in , as they assess the safety and effectiveness of new therapies in both humans and animal models. These investigations are essential for understanding , along with potential side effects within a living system. For example, research involving living organisms provides critical insights into how a medication interacts with various biological systems over time, revealing effects that are often unattainable through alternative methods. At Bioaccess, we leverage our expertise in managing – including feasibility assessments and project management – to ensure that is executed efficiently and effectively, ultimately contributing to the trial’s success.

    Conversely, in the early phases of medication development, particularly for evaluating compounds and understanding cellular responses to therapies. They enable high-throughput screening of treatment candidates, toxicity assessments, and exploration of mechanisms of action in a controlled environment. In fact, often represent the initial phase of the drug discovery process, allowing researchers to swiftly develop new therapies without the ethical dilemmas associated with animal testing.

    The decision between largely hinges on the specific research question at hand. Many investigations benefit from a synergistic combination of both techniques, as the comparison of provides a more comprehensive understanding of treatment effects. As the field progresses, the integration of advanced technologies, such as in silico modeling, is anticipated to further enhance the efficiency and accuracy of drug development processes, ensuring that innovative therapies reach patients more rapidly. With Bioaccess’s extensive – including feasibility evaluations, site selection, compliance assessments, and project oversight – we are well-equipped to navigate the complexities of both in-life and in-laboratory research.

    The central node represents the overall topic of clinical research approaches. The branches show the two main methods, with further details on their applications and benefits. This layout helps you understand how each method contributes to drug development and the factors influencing their use.

    Analyze Pros and Cons: Effectiveness of In Vivo and In Vitro

    In , the choice of methodologies – whether in vivo or laboratory-based – holds significant implications for the outcomes of studies. stand out for their physiological relevance, allowing researchers to observe treatment effects within the intricate environment of a living organism. This context often yields more reliable data regarding . However, these investigations can be costly, time-consuming, and raise ethical concerns, particularly regarding animal welfare. For instance, the daily observation required in mouse ascites methods can lead to distress for the animals involved, underscoring the of such approaches. Recent statistics reveal that can be considerably more expensive, with in situ methods costing between ½ to 6 times more than the mouse ascites technique for generating monoclonal antibodies, highlighting the financial factors in selecting a methodology.

    Conversely, offer a controlled environment that facilitates the manipulation of specific variables, resulting in quicker outcomes and reduced costs. They are particularly beneficial for initial drug candidate screenings and mechanistic investigations. Nevertheless, a significant limitation of laboratory methodologies is their inability to replicate the complex interactions found in living organisms, which can lead to discrepancies when translating findings to clinical applications. For example, recent have struggled to model the competition and interaction of microbes in the human body, potentially overlooking critical relationships that contribute to chronic diseases.

    Ultimately, the decision between methods depends on the , specific research goals, available resources, and ethical considerations. As ers navigate these choices, integrating both methodologies is often regarded as the gold standard, providing a comprehensive understanding of interactions from the test tube to human trials. As Grant Virellan aptly noted, ‘In living studies encompass complexity,’ emphasizing the importance of understanding medication interactions in a natural setting. This dual approach is essential for achieving reliable and applicable results in .

    The central node represents the overall topic, while the branches show the two methodologies. Each sub-branch lists the advantages and disadvantages, helping you see the trade-offs involved in choosing a research method.

    Integrate Approaches: Combining In Vivo and In Vitro for Enhanced Research Outcomes

    Combining live and significantly enhances the quality and reliability of . This approach not only utilizes the strengths of both methods but also allows researchers to gain a more thorough understanding of medication effects. For instance, preliminary laboratory experiments can pinpoint promising medication candidates, which are then confirmed through to evaluate their effectiveness and safety within a living organism. Such a sequential approach streamlines the research process and mitigates the risk of late-stage failures in .

    Recent advancements, particularly organ-on-chip technology, have further improved . These innovations enable laboratories to closely replicate living conditions, effectively bridging the gap between invivo vs methodologies. Ultimately, this combination fosters a , leading to improved patient outcomes and more efficient . As the evolves, the collaboration between these methodologies becomes increasingly vital in addressing key challenges in clinical research.

    Each box represents a step in the research process. Follow the arrows to see how laboratory findings lead to live testing and ultimately improve research outcomes.

    Conclusion

    The exploration of in vivo and in vitro methodologies reveals their distinct yet complementary roles in clinical research. Understanding these two approaches is essential for advancing medical science, as each offers unique insights that contribute to the development of effective therapies. The integration of both methods not only enhances the validity of research findings but also ensures a more comprehensive assessment of treatment effects.

    Key arguments throughout the article illustrate the advantages and limitations of each methodology. In vivo studies provide physiological relevance and insights into complex biological interactions, while in vitro experiments allow for controlled, rapid evaluations of drug candidates. The combination of these methodologies, particularly with advancements like organ-on-chip technology, represents a significant evolution in research practices, paving the way for improved patient outcomes.

    As clinical research continues to evolve, embracing a synergistic approach that leverages both in vivo and in vitro techniques is crucial. This integrated strategy addresses the complexities of drug development and fosters innovation in therapeutic interventions. By prioritizing collaboration between these methodologies, researchers can navigate the challenges of clinical studies more effectively, ultimately enhancing the journey from laboratory discovery to clinical application.

    Frequently Asked Questions

    What do the terms in vivo and in vitro mean?

    In vivo means “within the living” and refers to research conducted inside a living organism, such as animal models or human clinical trials. In vitro means “in glass” and involves experiments conducted outside of living organisms, typically in controlled laboratory environments like petri dishes or test tubes.

    What are the advantages of in vivo research?

    In vivo research allows researchers to observe biological processes in their natural context, providing insights into complex interactions within tissues and systems. It is crucial for assessing drug effectiveness and safety, as it demonstrates how therapies engage with various biological systems.

    What are the benefits of in vitro research?

    In vitro research enables researchers to isolate specific variables and examine cellular mechanisms in detail. It often results in quicker outcomes and has fewer ethical concerns related to animal testing, making it especially beneficial in initial research phases.

    How are in vivo and in vitro methodologies used in clinical trials?

    In vivo methodologies are used for human clinical trials and animal studies to assess drug effectiveness and safety, while in vitro methodologies are commonly used for initial testing of substances before progressing to more complex in vivo trials.

    What is the current trend in clinical trials regarding in vivo and in vitro techniques?

    Recent trends indicate an increasing dependence on in vitro techniques for initial testing, with around 70% of clinical trials incorporating in vitro methods as they advance.

    Why is it important to understand the distinctions between in vivo and in vitro research?

    Understanding the distinctions between these two methodologies is crucial for assessing scientific discoveries and their implications for clinical practice, as each offers unique advantages and limitations in the context of medical knowledge and drug development.

    List of Sources

    1. Define In Vivo and In Vitro: Key Concepts in Clinical Research
      • biointron.com (https://biointron.com/blog/in-vivo-vs-in-vitro-understanding-the-differences.html)
      • science.howstuffworks.com (https://science.howstuffworks.com/life/cellular-microscopic/in-vivo-vs-in-vitro.htm)
      • invivobiosystems.com (https://invivobiosystems.com/drug-discovery/the-in-vitro-vivo-silicos-and-outs-of-research)
      • biospace.com (https://biospace.com/fda/opinion-addressing-the-regulatory-reality-of-replacing-in-vivo-models-in-drug-development)
      • medicalnewstoday.com (https://medicalnewstoday.com/articles/in-vivo-vs-in-vitro)
    2. Explore Applications: In Vivo vs. In Vitro in Clinical Research
      • invivobiosystems.com (https://invivobiosystems.com/drug-discovery/the-in-vitro-vivo-silicos-and-outs-of-research)
      • Statistics in clinical trials: Key concepts – EUPATI Toolbox (https://toolbox.eupati.eu/resources/statistics-in-clinical-trials-key-concepts)
      • aacr.org (https://aacr.org/blog/2026/01/08/experts-forecast-cancer-research-and-treatment-advances-in-2026)
      • zeclinics.com (https://zeclinics.com/blog/differences-between-in-vitro-in-vivo-and-in-silico-assays-in-preclinical-research)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC4476988)
    3. Analyze Pros and Cons: Effectiveness of In Vivo and In Vitro
      • technologynetworks.com (https://technologynetworks.com/drug-discovery/articles/in-vivo-vs-in-vitro-definition-pros-and-cons-350415)
      • zeclinics.com (https://zeclinics.com/blog/differences-between-in-vitro-in-vivo-and-in-silico-assays-in-preclinical-research)
      • ncbi.nlm.nih.gov (https://ncbi.nlm.nih.gov/books/NBK100200)
      • science.howstuffworks.com (https://science.howstuffworks.com/life/cellular-microscopic/in-vivo-vs-in-vitro.htm)
    4. Integrate Approaches: Combining In Vivo and In Vitro for Enhanced Research Outcomes
      • regulatoryrapporteur.org (https://regulatoryrapporteur.org/case-studies-the-impact-of-the-in-vitro-diagnostic-regulation-on-atmp-clinical-trials-and-drug-development-plans/886.article)
      • Quotes About Medical Research (https://changingthepresent.org/pages/quotes-about-medical-research)
      • science.howstuffworks.com (https://science.howstuffworks.com/life/cellular-microscopic/in-vivo-vs-in-vitro.htm)
      • assaygenie.com (https://assaygenie.com/in-vitro-vs-in-vivo-complete-comparison-selection-guide-research-methods?srsltid=AfmBOoppnel0SJnH22EfNdu3usE6mFe0acSBLuVl3-6BFenSwYJzqZap)
      • newsnetwork.mayoclinic.org (https://newsnetwork.mayoclinic.org/discussion/weve-only-just-begun-to-glimpse-what-is-possible-and-more-thought-provoking-quotes-from-mayo-clinics-10th-annual-individualizing-medicine-conference)

  • Master Approval Timelines for CTAs in Montenegro: A Complete Guide

    Master Approval Timelines for CTAs in Montenegro: A Complete Guide

    Introduction

    Navigating the regulatory landscape for Clinical Trial Applications (CTAs) in Montenegro presents significant challenges, particularly as the stakes for patient safety and research integrity escalate. This guide provides a thorough examination of the approval timelines and processes, highlighting the essential steps required to secure authorization.

    With recent shifts in the regulatory framework and the potential for delays, how can researchers ensure their applications are processed efficiently and effectively? Understanding these dynamics is crucial for success in clinical research.

    Explore the Regulatory Landscape for CTAs in Montenegro

    The for in Montenegro, including the , is governed by the Law on Medicines and the Rulebook on Clinical Trials. The serves as the key authority overseeing the , ensuring compliance with European and international standards. Understanding the following aspects is crucial:

    • : The AMMD evaluates CTAs, playing a pivotal role in maintaining the integrity and safety of clinical trials.
    • Legislation: Familiarity with relevant laws and regulations is essential, as they outline the requirements for clinical studies, including .
    • : Local must provide a favorable opinion before a CTA can be submitted, ensuring that ethical standards are upheld.
    • : Applicants must prepare comprehensive documentation, including the clinical trial protocol, informed consent forms, and investigator brochures, which are critical for a .

    Recent statistics indicate that the AMMD has simplified the authorization method, significantly shortening the . For instance, the implementation of a centralized submission system has led to faster processing times, enabling quicker access to innovative treatments for patients. Successful case studies highlight the efficiency of the AMMD’s methods, illustrating how sponsors have navigated the to achieve prompt authorizations. By grasping these elements, you will be better equipped to navigate the complexities of the CTA procedure in Montenegro.

    Start at the center with the main topic, then explore each branch to understand the key components of the regulatory landscape. Each color-coded branch represents a different aspect of the CTA process, helping you see how they connect and contribute to the overall framework.

    The represent a critical pathway that ensures compliance with . Understanding this process is essential for anyone involved in , as it directly impacts the efficiency and success of studies.

    Preparation of Documentation: Start by compiling all , including the clinical trial protocol, informed consent forms, and any additional data required by the regulatory authority for Medicines and Medical Devices. This foundational step sets the stage for a smooth approval process.

    : Next, submit your application to the local ethics committee for review. A favorable opinion from this committee is not just a formality; it is mandatory before you can proceed to the next step. This ensures that ethical considerations are prioritized in your research.

    : Once you have obtained ethics consent, send your CTA to the regulatory body. The review process typically spans 30 to 90 days. Be aware that requires three specific documents, which are crucial for timely approval.

    Response to Questions: Prepare to address any inquiries or requests for additional information from the management. This step is vital, as delays in responding can prolong the overall timeline for consent, impacting your project schedule.

    : After a successful review, you will receive a notification of authorization, enabling you to commence your clinical study. This final step is a significant milestone, marking the transition from planning to execution.

    Understanding these steps and the approval timelines for CTA in Montenegro is crucial for managing expectations and optimizing project planning. Notably, the regulatory procedure for approvals is generally completed within a 60-day review period, with the AMMD often issuing approvals within 30 days for straightforward applications. This efficiency is vital for sponsors aiming to expedite their initiatives.

    Each box represents a step in the approval journey. Follow the arrows to see how each step leads to the next, from preparing documents to receiving authorization.

    Overcome Challenges and Implement Best Practices for CTA Success

    Navigating the presents several challenges that necessitate strategic approaches. Here are key obstacles and best practices to effectively address them:

    • : Meticulously prepare and ensure the accuracy of all required documents to prevent delays. Utilizing can help verify that no essential information is overlooked.
    • : Early engagement with the ethics committee is crucial. Proactively addressing potential concerns can significantly expedite their review process. Statistics indicate that timely communication can reduce review delays, often a bottleneck in the .
    • : Establish and maintain open lines of communication with the Agency for Medicinal Products and Medical Devices (AMMD). Regular updates and proactive inquiries can clarify expectations and streamline timelines, fostering a collaborative relationship.
    • : Allocate sufficient resources, including skilled personnel and budget, to manage the CTA procedure effectively. Engaging experienced regulatory consultants can provide valuable insights and support throughout the submission process.
    • : Invest in training programs for your team focused on the regulatory environment and best practices for clinical studies in Montenegro. This investment enhances compliance and operational efficiency, ultimately leading to more successful submissions.

    By implementing these best practices, you can significantly enhance your chances of a successful CTA submission in Montenegro.

    The central node represents the overall goal of achieving CTA success. Each branch shows a specific challenge, and the sub-branches outline the best practices to overcome those challenges. Follow the branches to see how to tackle each obstacle effectively.

    Understand Post-Approval Requirements and Compliance in Clinical Trials

    Upon approval of your (CTA), several essential post-approval requirements must be adhered to in Montenegro:

    • : Establish a comprehensive monitoring system to track trial progress and ensure adherence to the approved protocol. Regular reporting of adverse events to the Agency for Medicinal Products and Medical Devices is mandatory. Statistics indicate that effective monitoring can significantly enhance , with more efficiently than traditional methods.
    • Modifications: Should any changes to the experiment protocol be necessary, it is crucial to before execution. This step ensures that all changes comply with regulatory standards.
    • : At the conclusion of the examination, a detailed final report must be submitted to the AMMD, outlining the outcomes and any significant findings. This report is vital for transparency and accountability in clinical research.
    • : All data gathered during the study must be managed in accordance with local regulations, ensuring it is readily available for audits. Effective practices are essential for maintaining the integrity of the study.
    • : If applicable, a plan should be established to . This ongoing assessment is critical for ensuring long-term patient safety and compliance with regulatory requirements.

    By thoroughly understanding and fulfilling these post-approval requirements, you can maintain compliance and significantly contribute to the overall success of your clinical trial.

    Each box represents a crucial step you need to follow after your clinical trial is approved. The arrows show the order in which these steps should be completed to ensure compliance and success.

    Conclusion

    Navigating the approval timelines for Clinical Trial Applications (CTAs) in Montenegro is crucial for ensuring compliance and facilitating the success of clinical research. Understanding the regulatory landscape, including the role of the Agency for Medicines and Medical Devices (AMMD) and the necessary documentation, empowers stakeholders to effectively manage the complexities of this process.

    This article outlines critical steps in the approval journey, from preparing comprehensive documentation to engaging with ethics committees and regulatory authorities. It underscores the importance of proactive communication and resource allocation to overcome common challenges and streamline the approval process. Moreover, adhering to post-approval requirements is vital, ensuring ongoing compliance and patient safety throughout the clinical trial lifecycle.

    Ultimately, mastering the approval timelines for CTAs in Montenegro not only enhances the efficiency of clinical research but also contributes to the broader goal of advancing medical innovation. By implementing best practices and fostering collaboration with regulatory bodies, researchers can navigate the complexities of the approval process, ensuring timely access to new treatments and improving patient outcomes. Embracing this knowledge equips stakeholders to make informed decisions and drive success in their clinical endeavors.

    Frequently Asked Questions

    What governs the regulatory framework for Clinical Trial Applications (CTAs) in Montenegro?

    The regulatory framework for CTAs in Montenegro is governed by the Law on Medicines and the Rulebook on Clinical Trials.

    Which authority oversees the approval timelines for CTAs in Montenegro?

    The Agency for Medicines and Medical Devices (AMMD) is the key authority overseeing the approval timelines for CTAs in Montenegro.

    What role does the AMMD play in the clinical trial process?

    The AMMD evaluates CTAs and plays a pivotal role in maintaining the integrity and safety of clinical trials in Montenegro.

    Why is familiarity with relevant laws and regulations important for conducting clinical studies?

    Familiarity with relevant laws and regulations is essential as they outline the requirements for clinical studies, including ethical considerations and patient safety protocols.

    What is the requirement regarding ethics committees before submitting a CTA?

    Local ethics committees must provide a favorable opinion before a CTA can be submitted to ensure that ethical standards are upheld.

    What documentation is required for a successful CTA application?

    Applicants must prepare comprehensive documentation, including the clinical trial protocol, informed consent forms, and investigator brochures.

    How has the AMMD affected the approval timelines for CTAs in Montenegro?

    The AMMD has simplified the authorization method, significantly shortening the approval timelines for CTAs, allowing quicker access to innovative treatments for patients.

    What recent changes have been made to the submission process for CTAs?

    The implementation of a centralized submission system has led to faster processing times for CTAs in Montenegro.

    Are there successful case studies that demonstrate the efficiency of the AMMD’s methods?

    Yes, successful case studies highlight the efficiency of the AMMD’s methods, illustrating how sponsors have navigated the regulatory framework to achieve prompt authorizations.

    List of Sources

    1. Explore the Regulatory Landscape for CTAs in Montenegro
      • linical.com (https://linical.com/articles-research/deciphering-the-new-regulatory-landscape-of-clinical-trials-across-europe)
      • catalogues.ema.europa.eu (https://catalogues.ema.europa.eu/institution/1000000173)
    2. Navigate the Approval Process and Timelines for CTAs
      • fortrea.com (https://fortrea.com/insights/preparing-and-looking-ahead-clinical-trials-regulation-and-ctis)
      • appliedclinicaltrialsonline.com (https://appliedclinicaltrialsonline.com/view/clinical-trials-serbia-strong-stronger)
      • bioaccessla.com (https://bioaccessla.com/blog/understanding-clinical-trial-registry-requirements-in-montenegro)
    3. Overcome Challenges and Implement Best Practices for CTA Success
      • linical.com (https://linical.com/articles-research/ctis-lessons-learned-and-best-practices-for-submissions)
      • propharmagroup.com (https://propharmagroup.com/thought-leadership/mastering-clinical-trial-submissions-in-europe-drug-developer-guide)
      • docshifter.com (https://docshifter.com/blog/clinical-trial-application)
      • csr-company.com (https://csr-company.com/resources-corner/words/memorable-quotes-ethics-csr-and-sustainability)
    4. Understand Post-Approval Requirements and Compliance in Clinical Trials
      • appliedclinicaltrialsonline.com (https://appliedclinicaltrialsonline.com/view/risk-based-monitoring-case-study-lessons-3389-subject-global-phase-iii-trial)
      • linical.com (https://linical.com/articles-research/deciphering-the-new-regulatory-landscape-of-clinical-trials-across-europe)
      • acrohealth.org (https://acrohealth.org/informed-content-hub/case-studies-for-centralized-monitoring-in-practice-in-2025)